Literature DB >> 11503005

The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans.

K Tsutsumi1, T Kotegawa, S Matsuki, Y Tanaka, Y Ishii, Y Kodama, M Kuranari, I Miyakawa, S Nakano.   

Abstract

OBJECTIVE: Our objective was to evaluate the activity of cytochrome P4501A2 (CYP1A2), xanthine oxidase (XO), and N-acetyltransferase 2 (NAT2) from early to late pregnancy and after delivery.
METHODS: Twelve women were studied on three occasions during pregnancy (early, 8-16 weeks' gestation; middle, 20-28 weeks' gestation; and late, 32-39 weeks' gestation) and about 1 month after delivery. Caffeine was used as a metabolic probe. After the women ingested a can or a bottle of caffeine-containing soft drink, urine samples were collected for 12 hours. The caffeine metabolites measured were 5-acetylamino-6-amino-3-methyluracil (AAMU), 1-methylxanthine (1X), 1-methyl-uric acid (1U), 1,7-dimethyl-uric acid (17U), and 1,7-dimethylxanthine (17X). The hepatic enzyme activities were estimated by the urinary caffeine metabolic ratios as follows: CYP1A2 = (AAMU + 1X + 1U)/17U; XO = 1U/(1X + 1U); NAT2 = AAMU/(AAMU + 1X + 1U).
RESULTS: Statistically significant differences were found in CYP1A2 (P < .0001) and NAT2 (P < .01). The mean metabolic ratios for CYP1A2 during pregnancy (6.80, 5.18, and 4.97 for the early phase, middle phase, and late phase, respectively) were significantly lower than the ratio after delivery (10.39). The mean metabolic ratio for NAT2 in the early phase (0.57) was significantly lower than after delivery (0.66). There was no significant difference in metabolic ratios for XO during pregnancy and after delivery.
CONCLUSION: The data demonstrate that pregnancy influences CYP1A2 and NAT2 activity. CYP1A2 activity decreases not only in late pregnancy but also in early and middle pregnancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11503005     DOI: 10.1067/mcp.2001.116495

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

2.  A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.

Authors:  Lu Gaohua; Khaled Abduljalil; Masoud Jamei; Trevor N Johnson; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

3.  Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.

Authors:  Hanna Nylén; Sofia Sergel; Lisa Forsberg; Synnöve Lindemalm; Leif Bertilsson; Katarina Wide; Ulf Diczfalusy
Journal:  Eur J Clin Pharmacol       Date:  2011-01-19       Impact factor: 2.953

4.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 5.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  Prescribing without evidence - pregnancy.

Authors:  Simon H L Thomas; Laura M Yates
Journal:  Br J Clin Pharmacol       Date:  2012-10       Impact factor: 4.335

7.  Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites.

Authors:  Tian Yu; Sarah C Campbell; Chris Stockmann; Casey Tak; Katherine Schoen; Erin A S Clark; Michael W Varner; Michael G Spigarelli; Catherine M T Sherwin
Journal:  J Clin Pharmacol       Date:  2015-12-22       Impact factor: 3.126

8.  A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.

Authors:  André Dallmann; Ibrahim Ince; Katrin Coboeken; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

9.  Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.

Authors:  James H Fischer; Gloria E Sarto; Jennifer Hardman; Loraine Endres; Thomas M Jenkins; Sarah J Kilpatrick; Hyunyoung Jeong; Stacie Geller; Kelly Deyo; Patricia A Fischer; Keith A Rodvold
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

10.  Pharmacokinetics of clomipramine during pregnancy.

Authors:  P G J Ter Horst; J H Proost; J P Smit; M T Vries; L T W de Jong-van de Berg; B Wilffert
Journal:  Eur J Clin Pharmacol       Date:  2015-09-29       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.